Trump Most Favored Nation Pricing Is More ‘GENEROUS’ In 2025 Than 2020

 
• By Michael McCaughan
  
However the benchmark is set, the current focus of MFN policy on Medicaid is inherently less threatening to biopharma companies that the Part B policies of the first Trump Administration. (Shutterstock)

More from Pricing Debate

More from Market Access